Delivery Order SPE2DR25D9102-SPE2DR26FDDS6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,588.89 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units) with an ultimate completion date of December 2, 2025. This delivery order, issued on November 7, 2025, operates under a firm fixed-price contract structure with no set-aside designation, allowing the contract to compete in the unrestricted federal procurement marketplace. DMS Pharmaceutical Group Inc., a woman-owned small...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on January 9, 2026, by the Defense Logistics Agency for the supply of Nuplazid 34 mg capsules in a 30-count package. This firm fixed-price delivery order, valued at $11,771.46, represents one of numerous orders issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency. The award carries no...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $10,586.94 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 10 mg tablets (30-count) with an ultimate completion date of January 5, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $3,529.63 to DMS Pharmaceutical Group Inc. for 30-count bottles of Nuplazid 34 mg capsules, with a completion date of January 15, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation. The delivery order represents a firm fixed-price purchase issued under DMS Pharmaceutical Group's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count). This firm fixed-price delivery order, issued on November 4, 2025, with an ultimate completion date of November 26, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency awarded a $23,542.92 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Nuplazid 34 mg capsules (30-count units) with an ultimate completion date of January 28, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. This delivery order was...
- The Defense Logistics Agency awarded a delivery order valued at $10,588.89 to DMS Pharmaceutical Group Inc. for 30 capsules of Nuplazid 34 mg on November 28, 2025. This firm fixed-price delivery order, issued without set-aside designation, will be performed in Park Ridge, Illinois, with an ultimate completion date of December 19, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Illinois, serves as the sole awardee and has been...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units) on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was issued without a set-aside designation and is being performed at the contractor's location in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is the prime...
- The Defense Logistics Agency awarded a $10,588.89 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count units). The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on September 29, 2025, for the supply of Nuplazid (pimavanserin) 34 mg capsules in quantities of 30 units. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this delivery order under a firm fixed-price contract with a ceiling value of $10,375.53. The order represents no set-aside designation and carries an ultimate completion date...
- SPE2DR25D9102Indefinite Delivery Contract
- SPE2DR25D9102-SPE2DR26FDDS6Delivery Order
The Defense Logistics Agency issued a delivery order valued at $11,771.46 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units) on January 9, 2026. This firm fixed-price delivery order, which carries an ultimate completion date of February 2, 2026, represents a pharmaceutical supply transaction without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected as the awardee for this medical supply requirement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to support recurring pharmaceutical and medical supply needs across Department of Defense healthcare facilities worldwide. The underlying IDC, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue firm fixed-price delivery orders for a comprehensive range of branded and generic prescription medications, biologics, and medical consumables. DMS Pharmaceutical Group's established performance across multiple therapeutic categories and product lines positions it as a critical supplier within the federal military medical system's pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 1/8/26 |